Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2025)

Spero Therapeutics' Total Current Liabilities history spans 10 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 81.93% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, down 81.93%, while the annual FY2025 figure was $8.9 million, 81.93% down from the prior year.
  • Total Current Liabilities reached $8.9 million in Q4 2025 per SPRO's latest filing, down from $13.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $69.2 million in Q1 2022 to a low of $8.9 million in Q4 2025.
  • Average Total Current Liabilities over 5 years is $27.1 million, with a median of $20.2 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: soared 289.57% in 2022, then plummeted 81.93% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $18.7 million in 2021, then increased by 15.96% to $21.6 million in 2022, then surged by 71.62% to $37.2 million in 2023, then skyrocketed by 32.09% to $49.1 million in 2024, then tumbled by 81.93% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Total Current Liabilities are $8.9 million (Q4 2025), $13.6 million (Q3 2025), and $14.9 million (Q2 2025).